The National Institute of Health (INS) is launching today, Monday, the Phase 2 clinical trial ECOVA-02 in Mozambique to evaluate the combined use of two different vaccines against covid-19 in adults.

This study will evaluate the safety and immunogenicity of a two-dose regimen using VeroCell and Johnson & Johnson vaccines, administered 28 days apart, compared with currently used counterpart regimens.

Both vaccines have been approved by the World Health Organization (WHO) and are currently part of the covid-19 vaccination program in Mozambique.

The trial is led by INS, with support from the International Vaccine Institute and funded by the Coalition for Innovation in Epidemic Response Preparedness.